Premium
Transcatheter arterial embolization therapy in cases of recurrent and advanced gynecologic cancer
Author(s) -
Harima Yoko,
Shiraishi Tomokuni,
Harima Keizo,
Sawada Satoshi,
Tanaka Yoshimasa
Publication year - 1989
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19890515)63:10<2077::aid-cncr2820631034>3.0.co;2-8
Subject(s) - medicine , arterial embolization , vesicovaginal fistula , gynecologic cancer , radiation therapy , surgery , embolization , survival rate , radiology , cancer , fistula , urology , ovarian cancer
Transcatheter internal iliac arterial embolization therapy (TAE) using Gelfoam particles was performed in 24 patients with recurrent gynecologic cancer and ten patients with advanced gynecologic cancer who had previously undergone radiotherapy. The tumor showed complete response (CR) to the therapy in six patients, partial response (PR) in 12, minor response (MR) in three, and no changes (NC) in 13 patients, with the response rate (CR + PR) of 52.9% (18 of 34). No serious or prolonged side effects were encountered except for vesicovaginal fistula in three patients and renal failure in one. The median duration of survival was 299 days, and the 1‐year cumulative survival rate was 32.5%. The factors that were associated with favorable outcome after TAE were good general condition, no distant metastases, tumors <5 cm in diameter, and responses to the therapy of PR or better. Thus, TAE appears useful for the treatment of recurrent and advanced gynecologic malignancies.